SUBSCRIBE
SUBSCRIBE
News   Business

BioAlliance Pharma : Q3 2008: Significant Progression and Consolidation of Fundamentals

October 30, 2008 | 
1 min read
PARIS--(BUSINESS WIRE)-- Regulatory News: BioAlliance Pharma SA (Paris:BIO), a specialty pharma company focused on the treatment of opportunistic infections in cancer and AIDS, announces a turnover of €1,545k for the third quarter of 2008.
Earnings Europe
MORE ON THIS TOPIC
Podcast
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
March 4, 2026
 · 
1 min read
 · 
Heather McKenzie
Businessman receiving large stacks of money from a giant hand. Concept of funding, venture capital, financial support, dividend, and profitable business.
Funding
Teva Bags $400M Backing From Blackstone To Advance Sanofi-Partnered Drug
March 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Handmade signboard with Closed inscription and striped rope hanging on pin on bright red background
Company closure
Bespoke Startup EveryONE Folds 1 Week After Plausible Mechanism Guidance
March 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Theravance Halves Headcount, Cans R&D Work After Phase 3 Fail
March 4, 2026
 · 
61 min read
 · 
BioSpace Editorial Staff